DNA TESTING CENTERS CORP (DNAT) financial statements (2020 and earlier)
Company profile
| Business Address |
2378 PARKHAVEN OAKVILLE, ON L6H 0E7 |
| State of Incorp. | FL |
| Fiscal Year End | December 31 |
| SIC | 2835 - In Vitro and In Vivo Diagnostic Substances (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in thousands)
| 12/31/2017 | 12/31/2016 | 12/31/2015 | |||
|---|---|---|---|---|---|
| ASSETS | |||||
| Current Assets | |||||
| Cash, cash equivalents, and short-term investments | 83 | 4 | 0 | ||
| Cash and cash equivalents | 83 | 4 | 0 | ||
| Other undisclosed current assets | 2 | 0 | |||
| Total current assets: | 83 | 6 | 0 | ||
| Noncurrent Assets | |||||
| Property, plant and equipment | 3 | 4 | 5 | ||
| Total noncurrent assets: | 3 | 4 | 5 | ||
| TOTAL ASSETS: | 87 | 10 | 5 | ||
| LIABILITIES AND EQUITY | |||||
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities, including: | 33 | ||||
| Other undisclosed accounts payable and accrued liabilities | 33 | ||||
| Due to related parties | 129 | ||||
| Other undisclosed current liabilities | 7 | ||||
| Total current liabilities: | 161 | 7 | |||
| Noncurrent Liabilities | |||||
| Other undisclosed liabilities | 120 | ||||
| Total liabilities: | 161 | 120 | 7 | ||
| Stockholders' equity | |||||
| Stockholders' equity attributable to parent | (75) | (110) | (1) | ||
| Common stock | 2 | 2 | 2 | ||
| Common stock, value, subscriptions | 100 | ||||
| Additional paid in capital | 221 | 221 | 169 | ||
| Accumulated other comprehensive loss | (23) | (10) | (10) | ||
| Accumulated deficit | (376) | (323) | (162) | ||
| Total stockholders' equity: | (75) | (110) | (1) | ||
| TOTAL LIABILITIES AND EQUITY: | 87 | 10 | 5 | ||
Income statement (P&L) ($ in thousands)
| 12/31/2017 | 12/31/2016 | 12/31/2015 | ||
|---|---|---|---|---|
| Revenues | 50 | 32 | 21 | |
| Cost of revenue (Cost of Goods and Services Sold) | (29) | |||
| Other undisclosed gross profit | (17) | |||
| Gross profit: | 21 | 15 | 21 | |
| Operating expenses | (74) | (14) | (122) | |
| Other operating expense, net | (101) | |||
| Operating income (loss): | (53) | 1 | (202) | |
| Nonoperating income (expense) (Foreign Currency Transaction gain, before Tax) | 1 | |||
| Income (loss) before gain (loss) on sale of properties: | (53) | 2 | (202) | |
| Other undisclosed net income | 101 | |||
| Net income (loss): | (53) | 2 | (101) | |
| Other undisclosed net loss attributable to parent | (163) | |||
| Net loss available to common stockholders, diluted: | (53) | (161) | (101) | |
Comprehensive Income ($ in thousands)
| 12/31/2017 | 12/31/2016 | 12/31/2015 | ||
|---|---|---|---|---|
| Net income (loss): | (53) | 2 | (101) | |
| Other comprehensive income (loss) | (161) | 101 | ||
| Comprehensive loss: | (53) | (160) | (0) | |
| Comprehensive income, net of tax, attributable to noncontrolling interest | 7 | |||
| Other undisclosed comprehensive loss, net of tax, attributable to parent | (13) | |||
| Comprehensive income (loss), net of tax, attributable to parent: | (65) | (160) | 7 | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.